TWI904281B - Magl抑制劑 - Google Patents
Magl抑制劑Info
- Publication number
- TWI904281B TWI904281B TW110141858A TW110141858A TWI904281B TW I904281 B TWI904281 B TW I904281B TW 110141858 A TW110141858 A TW 110141858A TW 110141858 A TW110141858 A TW 110141858A TW I904281 B TWI904281 B TW I904281B
- Authority
- TW
- Taiwan
- Prior art keywords
- azaspiro
- octane
- hexafluoroprop
- ester
- carboxylic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063113662P | 2020-11-13 | 2020-11-13 | |
| US63/113,662 | 2020-11-13 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202229255A TW202229255A (zh) | 2022-08-01 |
| TWI904281B true TWI904281B (zh) | 2025-11-11 |
Family
ID=78709459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110141858A TWI904281B (zh) | 2020-11-13 | 2021-11-10 | Magl抑制劑 |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US11434222B2 (https=) |
| EP (2) | EP4574150A3 (https=) |
| JP (1) | JP2023549051A (https=) |
| KR (1) | KR20230107225A (https=) |
| CN (2) | CN116547274B (https=) |
| AR (1) | AR124057A1 (https=) |
| AU (1) | AU2021379081A1 (https=) |
| CA (1) | CA3196119A1 (https=) |
| CL (1) | CL2023001339A1 (https=) |
| CO (1) | CO2023004649A2 (https=) |
| CR (1) | CR20230203A (https=) |
| DK (1) | DK4244208T3 (https=) |
| DO (1) | DOP2023000086A (https=) |
| ES (1) | ES3025484T3 (https=) |
| FI (1) | FI4244208T3 (https=) |
| GE (2) | GEP20257794B (https=) |
| HR (1) | HRP20250644T1 (https=) |
| HU (1) | HUE071543T2 (https=) |
| IL (1) | IL301818B1 (https=) |
| JO (1) | JOP20230091A1 (https=) |
| LT (1) | LT4244208T (https=) |
| MA (1) | MA62148B1 (https=) |
| MX (1) | MX2023005576A (https=) |
| PL (1) | PL4244208T3 (https=) |
| PT (1) | PT4244208T (https=) |
| RS (1) | RS66839B1 (https=) |
| SA (1) | SA523440403B1 (https=) |
| SI (1) | SI4244208T1 (https=) |
| TW (1) | TWI904281B (https=) |
| UA (1) | UA130186C2 (https=) |
| UY (1) | UY39516A (https=) |
| WO (1) | WO2022101412A1 (https=) |
| ZA (1) | ZA202304134B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| CA3242372A1 (en) | 2021-12-29 | 2023-07-06 | Psy Therapeutics, Inc. | Inhibiting monoacylglycerol lipase (magl) |
| KR20250005229A (ko) | 2022-05-04 | 2025-01-09 | 하. 룬드벡 아크티에셀스카브 | 모노아실글리세롤 리파제 억제제로서 1,1,1,3,3,3-헥사플루오로프로판-2-일 (s)-1-(피리다진-3-일카르바모일)-6 아자스피로[2.5]옥탄-6-카르복실레이트의 결정질 형태 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017197192A1 (en) * | 2016-05-12 | 2017-11-16 | Abide Therapeutics, Inc. | Spirocycle compounds and methods of making and using same |
| WO2019046330A1 (en) * | 2017-08-29 | 2019-03-07 | Abide Therapeutics, Inc. | SPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2429991A (en) * | 2005-09-07 | 2007-03-14 | Alan Barrows | Water powered impulsive unit |
| US20110172230A1 (en) | 2006-08-23 | 2011-07-14 | Takahiro Ishii | Urea compound or salt thereof |
| TW200902007A (en) * | 2007-05-25 | 2009-01-16 | Astrazeneca Ab | Spirocyclopropyl piperidine derivatives |
| US20100113465A1 (en) * | 2008-10-30 | 2010-05-06 | Pfizer Inc. | 7-azaspiro[3.5]nonane-7-carboxamide compounds |
| US20120083476A1 (en) | 2009-06-05 | 2012-04-05 | Janssen Pharmaceutica Nv | Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase |
| FR2960875B1 (fr) * | 2010-06-04 | 2012-12-28 | Sanofi Aventis | Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique |
| WO2012047703A2 (en) * | 2010-10-04 | 2012-04-12 | Schering Corporation | Cyclopropyl-spiro-piperidines useful as sodium channel blockers |
| US9487495B2 (en) | 2012-01-06 | 2016-11-08 | The Scripts Research Institute | Carbamate compounds and of making and using same |
| US9822129B2 (en) * | 2012-03-02 | 2017-11-21 | Genentech, Inc. | Amido spirocyclic amide and sulfonamide derivatives |
| MX368615B (es) | 2012-09-25 | 2019-10-09 | Hoffmann La Roche | Derivados bicíclicos como inhibidores de la autotaxina (atx) que son inhibidores de la producción de ácido lisofosfatídico (lpa) y el uso de los mismos. |
| CA2917050A1 (en) | 2013-07-03 | 2015-01-08 | Todd K. Jones | Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof |
| CU24442B1 (es) | 2014-04-04 | 2019-09-04 | X Rx Inc | Derivados de n-(1-(espirocíclico)oxo) amida sustituidos como inhibidores de autotaxina |
| ES2878041T3 (es) | 2015-03-18 | 2021-11-18 | H Lundbeck As | Carbamatos de piperazina y métodos para prepararlos y usarlos |
| UA121775C2 (uk) | 2015-07-31 | 2020-07-27 | Пфайзер Інк. | 1,1,1-трифтор-3-гідроксипропан-2-ілкарбаматні похідні та 1,1,1-трифтор-4-гідроксибутан-2-ілкарбаматні похідні як інгібітори magl |
| EP3340988B1 (en) * | 2015-11-12 | 2025-04-09 | Afasci, Inc. | Ion channel inhibitory compounds, pharmaceutical formulations and uses |
| EA036637B1 (ru) | 2016-03-31 | 2020-12-02 | Такеда Фармасьютикал Компани Лимитед | Гетероциклические спиросоединения, ингибирующие моноацилглицерин-липазу |
| JOP20190105A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| EP3571202B1 (en) * | 2017-01-23 | 2021-06-30 | Pfizer Inc. | Heterocyclic spiro compounds as magl inhibitors |
| JP7257387B2 (ja) * | 2017-08-29 | 2023-04-13 | ハー・ルンドベック・アクチエゼルスカベット | スピロ環化合物並びにその作製及び使用方法 |
| KR20250005229A (ko) * | 2022-05-04 | 2025-01-09 | 하. 룬드벡 아크티에셀스카브 | 모노아실글리세롤 리파제 억제제로서 1,1,1,3,3,3-헥사플루오로프로판-2-일 (s)-1-(피리다진-3-일카르바모일)-6 아자스피로[2.5]옥탄-6-카르복실레이트의 결정질 형태 |
-
2021
- 2021-11-10 TW TW110141858A patent/TWI904281B/zh active
- 2021-11-11 US US17/524,632 patent/US11434222B2/en active Active
- 2021-11-11 UY UY0001039516A patent/UY39516A/es unknown
- 2021-11-12 US US18/252,611 patent/US20240018120A1/en active Pending
- 2021-11-12 IL IL301818A patent/IL301818B1/en unknown
- 2021-11-12 AU AU2021379081A patent/AU2021379081A1/en active Pending
- 2021-11-12 GE GEAP202116246A patent/GEP20257794B/en unknown
- 2021-11-12 EP EP25166976.8A patent/EP4574150A3/en active Pending
- 2021-11-12 HU HUE21811018A patent/HUE071543T2/hu unknown
- 2021-11-12 CR CR20230203A patent/CR20230203A/es unknown
- 2021-11-12 GE GEAP202516246A patent/GEAP202516246A/en unknown
- 2021-11-12 SI SI202130311T patent/SI4244208T1/sl unknown
- 2021-11-12 KR KR1020237015365A patent/KR20230107225A/ko active Pending
- 2021-11-12 PT PT218110187T patent/PT4244208T/pt unknown
- 2021-11-12 FI FIEP21811018.7T patent/FI4244208T3/fi active
- 2021-11-12 HR HRP20250644TT patent/HRP20250644T1/hr unknown
- 2021-11-12 PL PL21811018.7T patent/PL4244208T3/pl unknown
- 2021-11-12 UA UAA202301351A patent/UA130186C2/uk unknown
- 2021-11-12 ES ES21811018T patent/ES3025484T3/es active Active
- 2021-11-12 JP JP2023524567A patent/JP2023549051A/ja active Pending
- 2021-11-12 CN CN202180073621.0A patent/CN116547274B/zh active Active
- 2021-11-12 MA MA62148A patent/MA62148B1/fr unknown
- 2021-11-12 CN CN202512011225.8A patent/CN121824488A/zh active Pending
- 2021-11-12 MX MX2023005576A patent/MX2023005576A/es unknown
- 2021-11-12 WO PCT/EP2021/081522 patent/WO2022101412A1/en not_active Ceased
- 2021-11-12 LT LTEPPCT/EP2021/081522T patent/LT4244208T/lt unknown
- 2021-11-12 RS RS20250496A patent/RS66839B1/sr unknown
- 2021-11-12 AR ARP210103142A patent/AR124057A1/es unknown
- 2021-11-12 CA CA3196119A patent/CA3196119A1/en active Pending
- 2021-11-12 EP EP21811018.7A patent/EP4244208B1/en active Active
- 2021-11-12 DK DK21811018.7T patent/DK4244208T3/da active
-
2023
- 2023-04-04 ZA ZA2023/04134A patent/ZA202304134B/en unknown
- 2023-04-14 CO CONC2023/0004649A patent/CO2023004649A2/es unknown
- 2023-04-17 SA SA523440403A patent/SA523440403B1/ar unknown
- 2023-05-01 JO JOJO/P/2023/0091A patent/JOP20230091A1/ar unknown
- 2023-05-02 DO DO2023000086A patent/DOP2023000086A/es unknown
- 2023-05-09 CL CL2023001339A patent/CL2023001339A1/es unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017197192A1 (en) * | 2016-05-12 | 2017-11-16 | Abide Therapeutics, Inc. | Spirocycle compounds and methods of making and using same |
| WO2019046330A1 (en) * | 2017-08-29 | 2019-03-07 | Abide Therapeutics, Inc. | SPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7280929B2 (ja) | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体 | |
| TWI904281B (zh) | Magl抑制劑 | |
| JP2021105028A (ja) | ヘテロ環式化合物およびそれらの使用 | |
| TWI664181B (zh) | 做為ｐｄｅ２抑制劑之經取代的［１，２，４］三唑并［１，５－ａ］嘧啶－７－基化合物 | |
| CN104203943B (zh) | 取代的嘧啶化合物及其作为syk抑制剂的用途 | |
| CN119487018A (zh) | 作为irak 4的配体导向降解剂的杂芳基化合物 | |
| KR20150130415A (ko) | 질환의 치료에 유용한 헤테로환식 화합물 | |
| KR20210150491A (ko) | 포스파티딜이노시톨 3-키나제 저해제 | |
| TWI701246B (zh) | 作為ＬＲＲＫ２抑制劑之新穎咪唑並［４，５－ｃ］喹啉衍生物 | |
| JP6786566B2 (ja) | ヘテロアリール化合物及びその使用方法 | |
| US20260078103A1 (en) | Isoquinolones as pi3k inhibitors | |
| CN121039104A (zh) | 被取代的吲唑丙酸衍生化合物及其作为ampk活化剂的用途 | |
| CN119137114A (zh) | 作为单酰基甘油脂肪酶抑制剂的(s)-1-(哒嗪-3-基氨基甲酰基)-6-氮杂螺[2.5]辛烷-6-甲酸1,1,1,3,3,3-六氟丙-2-酯的结晶形式 | |
| CN115427409A (zh) | 作为trpv4拮抗剂的嘧啶-4(3h)-酮衍生物 | |
| HK40100721B (en) | A magl inhibitor | |
| HK40100721A (en) | A magl inhibitor | |
| EA048915B1 (ru) | Ингибитор magl | |
| HK40078094A (en) | Pyrimidin-4(3h)-one derivatives as trpv4 antagonists | |
| HK40028779A (en) | Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors | |
| HK40005135A (en) | Pyrazole derivatives, compositions and therapeutic use thereof | |
| HK1245259B (zh) | 作为nmda受体调节剂的吡啶并嘧啶酮类及它们的用途 |